Abstract 16714: Real-World Cost of All-Cause Hospitalizations Over a 12-Month Period After Acute Venous Thromboembolism
Recent clinical trial data have shown that newer oral anticoagulants may reduce all-cause hospitalizations in patients with venous thromboembolism (VTE) who complete anticoagulation therapy for 6-12 months. To understand the potential cost implications of such hospitalization reductions, this study sought to quantify the real-world cost of all-cause hospitalizations over a 12-month period after acute VTE.
This was a retrospective cohort study using U.S. health insurance claims data. Patients included in the study were aged ≥18 years, had experienced a non-fatal hospitalization or ED visit with a principal diagnosis of VTE between 1-Jan-2007 and 31-Mar-2013 (first visit=index) and had ≥1 claim for anticoagulation (warfarin, enoxaparin, rivaroxaban) or placement of an inferior vena cava filter ≤30 days after index. For up-to one year after discharge from the hospitalization or ED visit for acute VTE, patients were followed to identify the occurrence and costs of all-cause hospitalizations. Multivariable regressions were used to compare per-patient per-month (PPPM) total healthcare costs between patients with vs. without a hospitalization during follow-up.
The final cohort included 123,665 patients (mean age 59 years, 50% male). During an overall mean follow-up of 284 days after discharge from the acute VTE event, 33,843 patients were hospitalized at least once for any cause within 1 year and 37% of these hospitalized patients had at least one hospitalization for VTE. Among patients who were hospitalized, mean (standard deviation) PPPM hospital length of stay and PPPM costs for hospitalizations were 1.4 (2.8) and $5,800 ($14,723) at 1 year. Adjusted incremental PPPM differences in total healthcare costs between patients with vs. without a hospitalization during the 1-year follow-up were $ $4,808 (P<0.001).
Conclusion: Hospitalizations within 1 year after acute VTE are common and costly. VTE treatments which reduce hospitalizations after acute VTE may confer substantial cost offsets.
Author Disclosures: A.F. Shorr: Consultant/Advisory Board; Modest; Astellas, Bayer, Bristol-Myers Squibb, Forest, Cubist, Pfizer Inc, Nabriva, and Tetraphases. Consultant/Advisory Board; Significant; Truven Health Analytics. S. Johnston: Employment; Significant; Truven Health Analytics. Y. Jing: Employment; Significant; Bristol-Myers Squibb. R.A. Schaiff: Employment; Significant; Pfizer Inc. J. Trocio: Employment; Significant; Pfizer Inc. E. Thomson: Employment; Significant; Truven Health Analytics. P. Juneau: Employment; Significant; Truven Health Analytics. J. Graham: Employment; Significant; Bristol-Myers Squibb.
- © 2014 by American Heart Association, Inc.